Continuing to expand its fibrotic disease franchise, Boehringer Ingelheim (BI) has acquired the rights to Enleofen’s preclinical interleukin-11 platform in which the latter is eligible to receive in excess of US$1 B in terms of upfront and additional milestone payments per product. The number of products involved in the deal has not been publicly disclosed. The deal reaffirms BI’s commitment to this therapy area and comes after the company discontinued development of BI 1467335 for the treatment of non-alcoholic steatohepatitis.